Food and drug administration gives breakthrough: sanctioning of Rezdiffra for non-alcoholic steatohepatitis
On March 14,2024, FDA i.e., the US food and drug administration, approved Rezdiffra (resmetirom) for treating noncirrhotic non-alcoholic steatohepatitis (NASH) in adults who may have moderate to advanced degrees of liver fibrosis. This is a game-changing moment for patients who until now had only diet and exercise as their options.
Authors
- Shrishti Agarwal
- Sanchit Mehta
Institutions
- B.J. Medical College (IN)
Publication Details
- Journal
- International Journal of Advances in Medicine
- Published
- 2024-12-23
- DOI
- https://doi.org/10.18203/2349-3933.ijam20243826
- Primary Topic
- Liver Disease Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00